Keros Therapeutics (NASDAQ:KROS) Issues Earnings Results

Keros Therapeutics (NASDAQ:KROS) announced its quarterly earnings data on Monday. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($1.25) by ($0.20), FiscalAI reports. Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.

Keros Therapeutics Price Performance

Shares of KROS stock traded up $0.04 during trading hours on Monday, reaching $10.11. The company had a trading volume of 154,110 shares, compared to its average volume of 348,319. The company has a market cap of $200.10 million, a price-to-earnings ratio of -3.36 and a beta of 0.97. Keros Therapeutics has a 12 month low of $9.69 and a 12 month high of $22.55. The business has a fifty day simple moving average of $10.70 and a 200-day simple moving average of $12.65.

Insider Activity

In related news, Director Alpna Seth sold 2,625 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.72, for a total transaction of $28,140.00. Following the transaction, the director directly owned 9,767 shares in the company, valued at approximately $104,702.24. The trade was a 21.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the sale, the director owned 9,767 shares of the company’s stock, valued at approximately $104,799.91. This trade represents a 21.18% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,425 shares of company stock worth $89,994 over the last quarter. Insiders own 12.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds have recently made changes to their positions in the business. Brooklyn Investment Group grew its position in Keros Therapeutics by 22,733.0% during the third quarter. Brooklyn Investment Group now owns 20,778 shares of the company’s stock valued at $329,000 after buying an additional 20,687 shares during the period. Creative Planning boosted its stake in Keros Therapeutics by 40.2% in the second quarter. Creative Planning now owns 24,226 shares of the company’s stock valued at $323,000 after acquiring an additional 6,948 shares during the last quarter. Lazard Asset Management LLC purchased a new position in Keros Therapeutics in the second quarter valued at about $291,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Keros Therapeutics during the 3rd quarter valued at approximately $287,000. Finally, VARCOV Co. purchased a new stake in shares of Keros Therapeutics during the 4th quarter worth approximately $261,000. 71.56% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on KROS. Zacks Research downgraded Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 29th. Weiss Ratings downgraded Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Finally, Wall Street Zen lowered Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $20.40.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.